NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

BridgeBio Pharma, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBBIO
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BBIO COVERAGE

What’s moving BridgeBio Pharma, Inc. now

Current reporting with the operating signal separated from the noise.

01
Acoramidis Demonstrates Real-World Benefit versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

BridgeBio Pharma, Inc.

The story matters when it changes BridgeBio Pharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The story matters when it changes BridgeBio Pharma, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary

BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary

Investors are testing whether BridgeBio Pharma, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BBIO filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-10 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-31 · Period 2026-08-31SEC ↗8-KMaterial company eventFiled 2026-08-17 · Period 2026-08-13SEC ↗8-KMaterial company eventFiled 2026-08-10 · Period 2026-08-10SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-06-22SEC ↗4Official SEC filingFiled 2026-09-21 · Period 2026-09-17SEC ↗
EARNINGS / QUARTERLY TRACKER

BridgeBio Pharma, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.